SCHEMBL23792008

SCHEMBL23792008

CC(C)c1sc(Nc2ncc(-c3cccs3)cc2C(=O)O)nc1-c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 2/20 0.39
▸ NEK2 P51955 1/20 0.39
▸ RORB Q92753 2/20 0.38
▸ ACLY P53396 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ CTSC P53634 1/20 0.36
▸ FTO Q9C0B1 1/20 0.35
▸ JUN P05412 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ BCR P11274 2/20 0.34
▸ BLM P54132 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23791999 0.90 FTO (0.41) DHODHMEN1KMT2AFTOMAPT
SCHEMBL23782401 0.90 DHODH (0.45) DHODHRORBABL1BCRKDR
SCHEMBL30173772 0.90 DHODH (0.45) DHODHRORBABL1BCRKDR
SCHEMBL23791849 0.85 FTO (0.40) NEK2ACLYMEN1KMT2AFTO
SCHEMBL23792271 0.84 KDM4E (0.42) DHODHACLYMEN1KMT2ACTSC
SCHEMBL23791998 0.83 DHODH (0.46) DHODHRORBMEN1KMT2ANFKB1
SCHEMBL23792005 0.83 DHODH (0.43) DHODHRORBBLMKDR
SCHEMBL25545830 0.82 MAPT (0.38) DHODHNEK2MEN1KMT2AMAPT
SCHEMBL23792226 0.80 KDM4E (0.45) ACLYMEN1KMT2APOLBJUN
SCHEMBL23782375 0.79 DHODH (0.41) DHODHMEN1KMT2ACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 DHODH 3236/4885NEK2 851/4885RORB 2834/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 DHODH 3236/4885NEK2 851/4885RORB 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback